myoscience Announces 25 USD Million Series E Financing Round (AcT)

REDWOOD CITY, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- myoscience, inc., the makers of iovera°, is pleased to announce that it has closed on $25 million in Series E financing. The funds for the Series E financing came entirely from existing investors. The iovera° system uses Focused Cold Therapy^TM to treat peripheral nerve conditions for both cosmetic and pain indications.

"We are all excited about the results of iovera° for cosmetic use in the European Union and Canada, and the growing potential of our product in the treatment of focal pain in the United States," says Clint Carnell, CEO of myoscience. "This financing demonstrates the high degree of commitment and confidence that the investors have in the company's potential."

"We are ready and willing to support the future growth of myoscience, expanding geography and indications to recognize the full potential of their platform technology," says Jan Pensaert of Valiance Asset Management Limited.

The Series E financing included the following existing investors: Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Saratoga Ventures, and Valiance Asset Management Limited.

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy^TM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581

CONTACT: Alexandra Mack, myoscience inc.
Tel: 00 1 650 421 0609
amack@myoscience.com